NSE: THYROCARE · Healthcare Service Provider
Snapshot
Growth · Profitability · Valuation · Strength · Conviction
Thyrocare Technologies Limited is an Indian diagnostic and preventive care company providing a wide range of medical testing services to patients, hospitals, and laboratories. It operates through diagnostic testing, imaging services, and other healthcare-related segments, notably leveraging its Aarogyam brand for wellness profiles.
The company generates revenue primarily through the provision of diagnostic testing services, the sale of medical consumables, and the distribution of radiopharmaceuticals. It operates a hub-and-spoke model to provide cost-effective, high-volume testing across India.
Growth is driven by the expansion of the Aarogyam wellness brand and the increasing demand for preventive healthcare services in India. The company continues to focus on scaling its diagnostic network and diversifying its product offerings in the medical consumables space.
Unlock AI insights, financials, peers and live data on Thyrocare Technologies Ltd. and 5,000+ companies — free.
REVENUE
₹829 Cr
TTM · consolidated
NET PROFIT
₹163 Cr
TTM · consolidated
EPS
₹21.21
TTM · consolidated
RETURN ON EQUITY
29.3%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
36.5%
TTM · consolidated
P/E
24.9x
Q4 FY26 · consolidated
EV/EBITDA
9.9x
Q4 FY26 · consolidated
EBITDA MARGIN
33.7%
TTM · consolidated
NET PROFIT MARGIN
21.7%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.0x
Q4 FY26 · consolidated
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Thyrocare Technologies Ltd.THYROCARE | 5,857 | 24.86 | 9.89 | 20.6% | 33.7% | 29.3% | 36.5% | -56.0% |
Vijaya Diagnostic Centre Ltd.VIJAYA | 9,130 | 83.93 | 40.52 | 19.5% | 43.9% | 20.7% | 22.6% | +37.3% |
Metropolis Healthcare Ltd.METROPOLIS | 9,100 | 19.73 | 28.04 | 23.6% | 25.9% | 13.9% | 17.4% | -70.8% |
Nephrocare Health ServicesNEPHROPLUS | 5,259 | — | — | — | 22.0% | — | — | — |
Krsnaa Diagnostics Ltd.KRSNAA | 1,832 | 17.47 | 8.92 | 7.8% | 33.0% | 11.2% | 14.7% | -34.5% |
Suraksha Diagnostic Ltd.SURAKSHA | 1,318 | 41.25 | 13.66 | — | 32.1% | 14.7% | 18.4% | -19.9% |
As of Q4 FY26
Thyrocare Technologies Ltd.
NSE: THYROCARE · Healthcare Service Provider
Snapshot
Growth · Profitability · Valuation · Strength · Conviction
Thyrocare Technologies Limited is an Indian diagnostic and preventive care company providing a wide range of medical testing services to patients, hospitals, and laboratories. It operates through diagnostic testing, imaging services, and other healthcare-related segments, notably leveraging its Aarogyam brand for wellness profiles.
The company generates revenue primarily through the provision of diagnostic testing services, the sale of medical consumables, and the distribution of radiopharmaceuticals. It operates a hub-and-spoke model to provide cost-effective, high-volume testing across India.
Growth is driven by the expansion of the Aarogyam wellness brand and the increasing demand for preventive healthcare services in India. The company continues to focus on scaling its diagnostic network and diversifying its product offerings in the medical consumables space.
Loading…
Unlock AI insights, financials, peers and live data on Thyrocare Technologies Ltd. and 5,000+ companies — free.
REVENUE
₹829 Cr
TTM · consolidated
NET PROFIT
₹163 Cr
TTM · consolidated
EPS
₹21.21
TTM · consolidated
RETURN ON EQUITY
29.3%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
36.5%
TTM · consolidated
P/E
24.9x
Q4 FY26 · consolidated
EV/EBITDA
9.9x
Q4 FY26 · consolidated
EBITDA MARGIN
33.7%
TTM · consolidated
NET PROFIT MARGIN
21.7%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.0x
Q4 FY26 · consolidated
As of Q4 FY26